Sanofi Pasteur and MSD announce intent to end joint vaccines operations in Europe
- Details
- Category: Sanofi
Sanofi Pasteur and MSD, known as Merck in the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.
GSK names winners of 2015 Discovery Fast Track Challenge
- Details
- Category: GlaxoSmithKline
GSK has announced the winners of its third Discovery Fast Track Challenge. The programme is sponsored by GSK's Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines.
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor.
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer
- Details
- Category: Pfizer
Merck, Pfizer and Verastem have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer.
Merck and the European Molecular Biology Laboratory announce drug discovery collaboration
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced today that it has entered into a research collaboration focused on cancer metabolism with the European Molecular Biology Laboratory (EMBL), located in Heidelberg, Germany.
AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine). Plendil was first approved in China in 1995 for the treatment of hypertension or high blood pressure and in 2015 achieved Product Sales of $189 million.
Acalabrutinib recommended for orphan drug designation in Europe for three indications
- Details
- Category: AstraZeneca
AstraZeneca and Acerta Pharma BV, a company in which AstraZeneca has a majority equity investment, have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
More Pharma News ...
- Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment
- Johnson & Johnson issues call for innovative ideas to reduce HIV infections in Sub-Saharan Africa
- Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
- Novartis shareholders approve all resolutions proposed by Board of Directors
- Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare
- Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
- Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.